Three weeks after disclosing a $55 million funding round, upstart anti-aging company Unity Biotechnology Inc. wants another $85 million in an initial public offering. Zeroing in on “cellular senescence” – when cells stop dividing and secrete proteins believed to damage nearby healthy tissue …
06
Apr